Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan

Jung-Lung Hsu1,2,3,4, Ming-Feng Liao2,6, Chun-Che Chu2, Hung-Chou Kuo2, Rong-Kuo Lyu2, Hong-Shiu Chang2, Chiung-Mei Chen6, Yih-Ru Wu2, Kuo-Hsuan Chang2, Yi-Ching Weng1,2, Chun-Wei Chang1,2, Hsing-I. Chiang1,2, Chih-Kuang Cheng1,2, Pai-Wei Lee5, Chin-Chang Huang2 & Long-Sun Ro2

Our study aimed to investigate the incidence, risk factors and time to occurrence of malignancy in patients with dermatomyositis (DM) and polymyositis (PM). The electronic medical records of 1100 patients with DM and 1164 patients with PM were studied between January 2001 and May 2019. Malignancies after myositis were diagnosed in 61 (5.55%) patients with DM and 38 (3.26%) patients with PM. The cumulative incidence of malignancies in patients with DM were significantly higher than patients with PM (hazard ratio = 1.78, log-rank p = 0.004). Patients with DM had a greater risk of developing malignancy than those with PM at 40–59 years old (p = 0.01). Most malignancies occurred within 1 year after the initial diagnosis of DM (n = 35; 57.38%). Nasopharyngeal cancer (NPC) was the most common type of malignancy in patients with DM (22.95%), followed by lung, and breast cancers. In patients with PM, colorectal, lung and hepatic malignancies were the top three types of malignancy. The risk factors for malignancy included old age (≥ 45 years old) and low serum levels of creatine phosphokinase (CPK) for patients with DM and male sex and low serum levels of CPK for patients with PM. Low serum levels of CPK in patients with myositis with malignancy represented a low degree of muscle destruction/inflammation, which might be attributed to activation of the PD-L1 pathway by tumor cells, thus inducing T-cell dysfunction mediating immune responses in myofibers. A treatment and follow-up algorithm should explore the occurrence of malignancy in different tissues and organs and suggested annual follow-ups for at least 5.5 years to cover the 80% cumulative incidence of malignancy in patients with DM and PM.

The risk factors for malignancy in patients with DM and PM included old age, male sex, cutaneous lesions, clinical characteristics and laboratory markers15. Regarding the type of malignancy, previous studies have shown that lung, ovarian, colorectal, bladder, breast and nasopharyngeal cancers as well as lymphoma are associated with DM, while lung, kidney, breast, bladder, endometrial, cervical, thyroid, and brain cancers as well as lymphoma are associated with PM16. Interestingly, studies from different countries and continents have revealed that different ethnic populations with myositis may be at risk for different malignancies, which indicates that there may be an ethnic effect in these diseases15. For example, nasopharyngeal carcinoma (NPC) showed a significantly higher frequency in Asian patients with DM than in European and North American patients with DM17. In addition, the frequency of malignancy in the general population during different study periods may affect the incidence of malignancy in patients with DM and PM.

1Department of Neurology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan. 2Department of Neurology, Chang Gung Memorial Hospital Linkou Medical Center and College of Medicine, Chang-Gung University, Linkou, Taoyuan, Taiwan. 3Graduate Institute of Mind Brain and Consciousness, Taipei Medical University, Taipei, Taiwan. 4Brain and Consciousness Research Center, Shuang Ho Hospital, New Taipei City, Taiwan. 5Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. 6These authors contributed equally: Jung-Lung Hsu and Ming-Feng Liao. *email: cgrols@adm.cgmh.org.tw
of myositis-associated malignancy. From 1997 to 2016, the most frequent malignancies changed from uterine cervical cancer and breast cancer to breast cancer and colorectal cancer in Taiwan. In the current study, we aimed to explore myositis-associated malignancy in a tertiary hospital and compare the results with those of previous studies in Taiwan.

Materials and methods

Subjects. We conducted a registry analysis using electronic medical records (EMRs) from the outpatient clinic and admission data from a tertiary medical center (the largest hospital in Taiwan) from January 2001 to May 2019. EMRs included demographic data, dates of clinical visits, diagnostic codes, and details of examinations. This study was based in part on data from the Chang Gung Research Database provided by Chang Gung Memorial Hospital. Subjects below 18 years of age were excluded. Diagnoses of DM and PM were based on the Bohan and Peter diagnostic criteria. The study protocol was approved by the Chang Gung Memorial Hospital Institutional Review Board (CGMHIRB201901511B0). The Chang Gung Memorial Hospital Institutional Review Board approved the waiver of the participants’ consent. All methods were performed in accordance with the relevant guidelines and regulations.

Diagnostic coding. Enrollees with DM with the International Classification of Diseases (ICD), ninth revision (ICD-9) code 7103 and ICD, tenth revision (ICD-10) codes M33, M3310, M3319, M3390, M3390, M360 or PM (or ICD-9 code 7104; or ICD-10 codes M3320 or M3329) were recruited. Amyopathic DM and inclusion body myositis were not identified due to a lack of specific diagnostic codes. Malignancies that were first diagnosed after the onset of myositis were included to assess the time-to-occurrence of cancer and malignancy risk factors after the diagnosis of myositis. Patients with a diagnosis of malignancy with the following codes were enrolled: malignant neoplasm of the lip, oral cavity or pharynx (ICD-9: 141, 145, 146, and 148; ICD-10: C02, C06, C09, C10, and C13); malignant neoplasm of the nasopharynx (ICD-9: 147; ICD-10: C11); malignant neoplasm of the esophagus (ICD-9: 150; ICD-10: C15); malignant neoplasm of the stomach (ICD-9: 151; ICD-10: C16); malignant neoplasm of the colon (ICD-9: 153; ICD-10: C18); malignant neoplasm of the rectum (ICD-9: 154; ICD-10: C20); malignant neoplasm of the liver and intrahepatic bile ducts (ICD-9: 155; ICD-10: C22); malignant neoplasm of other or unspecified parts of the biliary tract (ICD-9: 156; ICD-10: C24); malignant neoplasm of the larynx (ICD-9: 161; ICD-10: C32); malignant neoplasm of the bronchus and lung (ICD-9: 162; ICD-10: C34); secondary and unspecified malignant neoplasm of lymph nodes or leukemia (ICD-9: 169 and 196; ICD-10: C42 and C77); malignant neoplasm of the breast (ICD-9: 174; ICD-10: C50); malignant neoplasm of the corpus uteri (ICD-9: 182; ICD-10: C54); malignant neoplasm of the ovary (ICD-9: 183; ICD-10: C56); malignant neoplasm of the prostate (ICD-9: 185; ICD-10: C61); malignant neoplasm of the bladder (ICD-9: 188; ICD-10: C67); and malignant neoplasm without specification of site (ICD-9: 199; ICD-10: C80). To study the malignant neoplasms associated with comorbidities, we selected diabetes mellitus (ICD-9: 250; ICD-10: I10, I110, I109, I110, I111, and I119), hypertension (ICD-9: 401 and 402; ICD-10: I10-I16), and idiopathic interstitial lung disease (ICD-9: 515 and 516; ICD-10: J841, J842, J849, and J8410).

Statistical analysis. The demographic data of the study population were first analyzed. We examined the ratios among groups with DM, PM and specific types of malignancy. Crude malignancy incidences in patients with DM or PM were calculated as follows: the number of malignant cases that occurred among DM or PM patients divided by the total number of patients with DM or PM within the predefined periods. To assess the effect of age on the relative risk of malignancy, we stratified patients aged 20–39 years, 40–59 years, 60–79 years, and > 80 years at the time of myositis diagnosis and estimated the malignancy frequencies in patients with DM and PM. The type of malignancy, age, sex and mean interval of malignancy onset after myositis diagnosis were documented for further comparisons. We divided the follow-up periods according to half-year intervals and recorded the case number and cumulative incidence of total malignancies within each period for patients with DM and PM. Annual reports of the different types of malignancy incidences were obtained from the Taiwan National Cancer Registry (TNCR) for comparison.

All statistical analyses were performed using SPSS (version 21.0; IBM, New York, USA). Continuous variables are expressed as the means ± standard deviations. Categorical variables are presented as numbers and ratios. Nonparametric Mann–Whitney U tests were performed to compare the mean onset age and plasma creatine phosphokinase (CPK) levels between groups. The CPK levels were determined upon diagnosis of myositis. Serum tumor markers such as carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) and autoimmune markers such as anti-nuclear antibody (ANA) and anti-double stranded DNA antibody (anti-dsDNA) and rheumatic factor (RF) were classified as positive or negative in patients with or without malignancy. Chi-squared tests and Fisher’s exact tests were used to compare myositis patients with and without malignancy in terms of age, sex, tumor markers, autoimmune markers and comorbidities. Kaplan–Meier analysis was used to compare the cumulative incidence probability of malignancy between patients with DM and PM. A Cox regression model was used to examine the hazard ratios of risk factors in patients with DM and PM. Statistical significance was defined as P < 0.05.

Results

Baseline characteristics. During the period of 2001–2019, we identified a total of 1100 patients with DM, of whom 68 patients diagnosed with malignancy prior to DM were excluded. A total of 1164 patients with PM were identified, and 38 patients diagnosed with malignancy prior to PM were excluded. The mean ± standard deviation of the age at diagnosis of patients with DM and PM was 49.11 ± 15.47 years and 48.53 ± 15.03 years,
respectively. Among DM patients, 395 (35.91%) were male and 705 (64.09%) were female. There were 463 (39.77%) male and 701 (60.23%) female patients in the PM group (Table 1).

The occurrence of malignancies in DM and PM patients. Malignancy was diagnosed in 61 (5.55%) patients with DM and 38 (3.26%) patients with PM. According to the chi-square test, patients with DM had a significantly higher malignancy incidence than those with PM (p = 0.008). Regarding the age-stratified malignancy incidence, patients with DM had a greater risk of developing malignancy than those with PM at 40–59 years old (p = 0.01). In other age ranges, no significant differences were found.

![Figure 1A](image.png)

![Figure 1B](image.png)

![Figure 1C](image.png)

Figure 1. Case number (A), cumulative incidence (B) and the proportion of malignancy (C) in patients with DM and PM after initial diagnosis are plotted against the follow-up period in half-year intervals. The cumulative incidence showed a significant difference between patients with DM and PM based on Kaplan–Meier analysis (hazard ratio = 1.78, log-rank p value = 0.004).

Table 1. Total and malignancy cases of DM and PM in the study population (2001–2019 May), by age and gender group. DM dermatomyositis, PM polymyositis, M male, F female; *p value: Chi-square or Fisher exact test between total DM and PM with or without malignancy.

| Age group (years) | DM (N=1100) | PM (N=1164) | p value* |
|------------------|-------------|-------------|----------|
|                  | Total M:F   | Total M:F   | Malignancy Total M:F | Malignancy Total M:F |
| 19               | 12 5:7      | 0 0:0      | 0 0:0 | 1 |
| 20–39            | 296 101:195 | 5 1:4 | 318 127:191 | 8 5:3 | 0.48 |
| 40–59            | 520 182:338 | 30 15:15 | 552 198:354 | 15 11:4 | 0.008 |
| 60–79            | 238 90:148 | 23 11:12 | 273 127:146 | 15 9:6 | 0.07 |
| ≥ 80             | 34 17:17 | 3 1:2 | 16 11:5 | 0 0:0 | 0.54 |
| All              | 1100 395:705 | 61 28:33 | 1164 463:701 | 38 25:13 | 0.008 |

Types of malignancy in patients with DM and PM. Table 2 shows information on the various types of malignancy diagnosed among patients with DM and PM. Overall, nasopharyngeal cancer (NPC) was the most common malignancy (22.95%) among patients with DM and was more common in male (83.33%) patients with DM than in female patients with DM. Ten of 14 patients were diagnosed with NPC within 1 year after the initial diagnosis of DM. Eight patients had squamous cell carcinoma, five patients had poorly differentiated carcinoma and one had carcinoma not otherwise specified (NOS). Breast cancer was the most common malignancy in female patients with DM (19.35%), and five of six patients had a pathological diagnosis of ductal...
Figure 2. Kaplan–Meier analysis of the malignancy cumulative incidence probability in patients with DM and PM stratified by age, sex and CPK results. Panels (A)–(C) show the malignancy cumulative incidence probability stratified by age, sex and CPK results in patients with DM. Age (≥ 45 years old) showed a significantly higher malignancy incidence (log rank p = 0.001). Panels (D)–(F) show the malignancy cumulative incidence probability stratified by age, sex and CPK results in patients with PM. Male patients had a significantly higher malignancy incidence (log rank p = 0.001). Although the CPK results did not show significant differences based on Kaplan–Meier analyses in patients with DM and PM, there were significant group differences in multivariate Cox regression models (all p < 0.05).
adenocarcinoma. Four of six patients were diagnosed with breast cancer within 1 year after the initial diagnosis of DM. One patient with DM had two malignancies (hepatoma and prostate cancer). Among patients with PM, malignancy of the colon and rectum (15.78%) was the most common malignancy type, and four of six patients had a pathological diagnosis of adenocarcinoma. Only two patients had a diagnosis of colorectal cancer within 1 year after the initial diagnosis of PM, but four patients had a mean interval of approximately 9 years (range 58–148 months) between the initial diagnosis of PM and the occurrence of cancer. Two patients with PM had two malignancies. One patient had colorectal cancer and cervical cancer. The other patient had bladder cancer and cancer of unknown origin.

### Risk factors for malignancy in patients with DM and PM.

To study the risk factors for malignancy in patients with DM and PM, we explored age, sex, diabetes mellitus, hypertension, idiopathic interstitial lung disease, plasma CPK levels, serum tumor markers and autoimmune markers in myositis patients with and without malignancy (Table 3). In patients with DM, old age (age ≥ 45 years old) and low serum levels of CPK showed a significant difference between the malignancy group and the nonmalignancy group (p = 0.003 and p = 0.05, respectively). However, sex, diabetes mellitus, hypertension and idiopathic interstitial lung disease did not show significant differences. DM patients with malignancy showed a significantly higher proportion of abnormal AFP and ANA results than patients without malignancy (p = 0.02 and p = 0.01, respectively) based on chi-squared tests. In patients with PM, male and low serum levels of CPK were significantly different between the patients with malignancy group and without malignancy group (p = 0.001, p = 0.003, respectively). PM patients with malignancy showed a significantly higher proportion of abnormal CEA and AFP results than patients without malignancy (p = 0.03 and p = 0.00, respectively).

In the univariate Cox regression model, old age (age ≥ 45 years old) was significantly associated with malignancy in patients with DM (hazard ratio = 2.72, p = 0.001). In patients with PM, male showed a significantly higher association with malignancy (hazard ratio = 2.86, p = 0.002). In the multivariate Cox regression model, old age (age ≥ 45 years old), male and low serum levels of CPK were significantly associated with malignancies in patients with DM (hazard ratios = 2.05, 2.24 and 2.48, respectively; all p < 0.05). In patients with PM, male and low serum levels of CPK showed significantly higher associations with malignancies (hazard ratios = 5.79 and 3.62, respectively; all p < 0.05) (Table 4).

### Incidences of malignancy compared with those in previous studies.

Table 5 shows a comparison of the crude malignancy incidences from the 2003 TNCR, 2016 TNCR, a previous study from the National Health Insurance Research Database (NHIRD) by Chen et al. and our work. Both our study and Chen’s study showed increased crude malignancy incidences compared with those in the general population. In TNCR data from 2003 to 2016, the three types of malignancy with the highest annual incidences changed from 2003 (breast, hepatic and colorectal) to 2016 (breast, colorectal and lung). During this period, increased incidences of breast, colon and rectal, prostate, esophageal, bladder, hematological and lung malignancies were found. Our results did not show a trend of increasing incidence in the above malignancies. Rather, NPC was the most frequent malignancy in our study and Chen’s study. We segregated our data into the 2001–2007 period so that the study period matched that of Chen’s study. The top three malignancies in patients with DM and PM from 2001 to 2007 were similar to those from 2001 to 2019 (Table 5). Our study showed an increased incidence of malignancy in
the oral cavity in patients with DM but a decreased incidence of malignancy of the breast in patients with PM compared with Chen’s study.

**Discussion**

The current study produced three major findings. First, we found that the crude malignancy incidences in patients with DM and PM were higher than those in the general population. The cumulative incidence of malignancies in patients with DM were significantly higher than patients with PM (hazard ratio = 1.78, log-rank p = 0.004). Specifically, the malignancy incidence in patients with DM ranging from 40 to 59 years old was significantly higher than that in patients with PM of the same age (p < 0.05). Second, the interval to the occurrence of malignancy showed a significant difference between patients with DM and PM. Patients with DM showed a significantly higher rate of occurrence of malignancy within 1 year after the initial diagnosis of myositis than those with PM (p < 0.05), which was similar to previous studies. There was a tendency for the cumulative malignancy incidence to be different between the different myositis groups (p = 0.07). It took 5.5 years and 9.5 years for more than 80% of the malignancy diagnoses to be made for patients with DM and PM, respectively. Third, different types of malignancy and risk factors were found. Patients with DM more frequently had NPC, while those with PM more frequently had colorectal cancer, lung cancer and hepatic cancer. The risk factors for malignancy in patients with DM were old age, a higher proportion of abnormal AFP and ANA results and low serum levels of CPK, while those for patients with PM were male, a higher proportion of abnormal CEA and AFP results and low serum levels of CPK.

| Variables | DM (N = 1100) | PM (N = 1164) | p values | DM (N = 1100) | PM (N = 1164) | p values |
|-----------|---------------|---------------|----------|---------------|---------------|----------|
| Age (years old) | Non-malignancy | Malignancy | p values | Non-malignancy | Malignancy | p values |
| < 45 | 424 | 13 | 0.0025 | 465 | 11 | 0.13 |
| ≥ 45 | 615 | 48 | | 661 | 27 | |
| Gender | Female | 672 | 33 | 0.09 | 688 | 13 | 0.001 |
| Male | 367 | 28 | | 438 | 25 | |
| Diabetes mellitus | No | 854 | 53 | 0.44 | 949 | 28 | 0.13 |
| Yes | 185 | 8 | | 177 | 10 | |
| Hypertension | No | 741 | 48 | 0.27 | 782 | 24 | 0.52 |
| Yes | 298 | 13 | | 344 | 14 | |
| IILD | No | 972 | 60 | 0.17* | 1092 | 36 | 0.30* |
| Yes | 67 | 1 | | 34 | 2 | |
| CPK | Abnormal | 196 | 6 | 0.05 | 280 | 4 | 0.04 |
| Normal | 420 | 33 | | 426 | 20 | |
| Levels of CPK (U/L) | 339.06 ± 965.50 | 221.00 ± 626.17 | 0.05* | 540.42 ± 1394.88 | 431.08 ± 1734.07 | 0.003* |
| CEA | Abnormal | 23 | 6 | 0.13* | 16 | 4 | 0.03* |
| Normal | 219 | 26 | | 221 | 12 | |
| AFP | Abnormal | 8 | 4 | 0.02 | 5 | 4 | 0.0004* |
| Normal | 225 | 21 | | 241 | 9 | |
| ANA | Abnormal | 143 | 18 | 0.01 | 131 | 3 | 0.58* |
| Normal | 317 | 16 | | 350 | 13 | |
| Anti-dsDNA | Abnormal | 8 | 0 | 1* | 15 | 0 | 1* |
| Normal | 228 | 22 | | 198 | 3 | |

Table 3. Statistic analysis of risk factors associated with PM/DM with and without malignancy. DM dermatomyositis, PM polymyositis, IILD idiopathic interstitial lung disease, CPK creatine phosphokinase, CEA carcinoembryonic antigen, AFP alpha fetoprotein, ANA anti-nuclear antibody, Anti-dsDNA and anti-double stranded DNA antibody; *Fisher exact test; #non-parametric Mann–Whitney U test.
The incidences of different types of malignancies in myositis.

Increased incidences of malignancies in myositis are a well-known issue; approximately 25% of patients with DM develop malignancy within 5 years of disease onset, which is higher than the 10–15% of patients with PM. In Taiwan, the incidences of malignancies in patients with DM and PM ranged from 9.4 to 23% and from 4.4 to 8.9%, respectively. Our results showed that the overall incidence of malignancy was 5.6% in DM and 3.3% in PM, and this differ-

### Table 4. Multivariate cox regression model analysis showed malignancy risk factors in patients with DM and PM. DM dermatomyositis, PM polymyositis, IILD idiopathic interstitial lung disease, CPK creatine phosphokinase, CI confidence interval.

|                        | DM (N=625)               | PM (N=703)               | Hazard ratios (95% CI) | p value | Hazard ratios (95% CI) | p value |
|------------------------|--------------------------|--------------------------|------------------------|---------|------------------------|---------|
| Age (years old)        |                          |                          |                        |         |                        |         |
| ≥ 45                   | 2.05 (1.01–4.15)         | 1.39 (0.58–3.38)         | 0.04                   | 0.46    |
| < 45                   |                          |                          |                        |         |                        |         |
| Gender                 |                          |                          |                        |         |                        |         |
| M                      | 2.24 (1.19–4.22)         | 5.79 (2.28–14.74)        | 0.01                   | 0.0002  |
| F (reference)          |                          |                          |                        |         |                        |         |
| Diabetes mellitus      |                          |                          |                        |         |                        |         |
| Yes                    | 0.19 (0.03–1.41)         | 1.37 (0.30–6.24)         | 0.10                   | 0.68    |
| No (reference)         |                          |                          |                        |         |                        |         |
| Hypertension           |                          |                          |                        |         |                        |         |
| Yes                    | 1.15 (0.39–3.34)         | 0.60 (0.17–2.20)         | 0.79                   | 0.44    |
| No (reference)         |                          |                          |                        |         |                        |         |
| IILD                   |                          |                          |                        |         |                        |         |
| Yes                    | 0.59 (0.08–4.29)         | 3.41 (0.45–26.11)        | 0.59                   | 0.24    |
| No (reference)         |                          |                          |                        |         |                        |         |
| CPK                    |                          |                          |                        |         |                        |         |
| Normal                 | 2.48 (1.03–5.96)         | 3.62 (1.22–10.72)        | 0.04                   | 0.02    |
| Abnormal (reference)   |                          |                          |                        |         |                        |         |

### Table 5. Crude malignancy incidence (per 100,000 person) from Taiwan National Cancer Registry (TNCR), National Health Insurance Research Database (NHIRD) and current work. DM dermatomyositis, PM polymyositis.

|                        | 2003 TNCR | 2016 TNCR | 1997–2007 Chen et al. from NHIRD | 2001–2019 | 2001–2007 |
|------------------------|-----------|-----------|-----------------------------------|-----------|-----------|
| DM (N=1012)            | 276.68    | 449.59    | 9387.35                           | 5132.19   | 5545.45   | 4553.41   | 1671.73   |
| PM (N=643)             |           |           | 3264.60                           |           | 4553.41   | 3264.60   |           |
| Total malignancy       | 276.68    | 449.59    | 9387.35                           | 5132.19   | 5545.45   | 4553.41   | 1671.73   |
| Malignant neoplasm of lip, oral cavity and pharynx | 27.05    | 33.16    | 98.81                             | 545.45   | 257.73   | 151.97   |
| Malignant neoplasm of nasopharynx | 6.67     | 6.45    | 2964.43                           | 311.04   | 1272.73  | 1401.05  |
| Malignant neoplasm of esophagus | 6.06     | 11.09    | 98.81                             | 90.91    | 85.91    | 175.13   |
| Malignant neoplasm of stomach | 15.63    | 15.54    | 98.81                             | 272.73   | 85.91    | 350.26   |
| Malignant neoplasm of colon and rectum | 36.44    | 65.31    | 494.07                           | 777.60   | 181.82   | 175.13   |
| Malignant neoplasm of liver and gall bladder | 44.45    | 51.69    | 494.07                           | 622.08   | 429.55   | 175.13   |
| Malignant neoplasm of larynx | 2.16     | 3.11     | 98.81                             |          |          |          |
| Malignant neoplasm of bronchus and lung | 32.80    | 57.30    | 2173.91                           | 777.60   | 636.36   | 525.39   |
| Secondary and unspecified malignant neoplasm of lymph nodes and leukemia | 7.80     | 15.75    | 395.26                           | 155.52   | 454.55   | 343.64   |
| Malignant neoplasm of breast | 48.02    | 107.20   | 889.33                           | 466.56   | 545.45   | 171.82   |
| Malignant neoplasm of corpus uteri | 34.56    | 20.83    | 296.44                           | 311.04   | 181.82   | 350.26   |
| Malignant neoplasm of ovary | 7.51     | 12.72    | 197.63                           |          |          |          |
| Malignant neoplasm of prostate | 19.43    | 45.73    | 98.81                             | 0.91     | 257.73   | 175.13   |
| Malignant neoplasm of bladder | 8.22     | 19.33    | 197.63                           | 311.04   | 257.73   | 175.13   |
| Other (pancreas, kidney, skin, bone, brain, thyroid) | 790.51 | 1399.69 | 545.45                           | 429.55   | 350.26   | 303.95   |

The incidences of different types of malignancies in myositis. Increased incidences of malignancies in myositis are a well-known issue; approximately 25% of patients with DM develop malignancy within 5 years of disease onset, which is higher than the 10–15% of patients with PM. In Taiwan, the incidences of malignancies in patients with DM and PM ranged from 9.4 to 23% and from 4.4 to 8.9%, respectively. Our results showed that the overall incidence of malignancy was 5.6% in DM and 3.3% in PM, and this differ-
DM has a closer association with NPC than with other malignancies in Asia. During our study period, we also recorded the total numbers of different malignancies. The top five malignancies were hepatoma (n = 37,463), colorectal cancer (n = 32,296), lung cancer (n = 26,168), breast cancer (n = 22,828) and oral cancer (n = 14,667). The total number of NPC cases was 5475. The incidences of DM in the above malignancies (total number of patients with DM/total number of malignancies per 100,000 persons) were 34.7, 15.48, 91.72, 65.71, and 61.36 for hepatoma, colorectal cancer, lung cancer, breast cancer, and oral cancer, respectively. The incidence of DM in NPC was 47.48 per 100,000 persons. On the other hand, the incidences of PM in the above malignancies (total number of patients with PM/total number of malignancies per 100,000 persons) were 26.69, 40.25, 22.93, 21.90, and 27.27 for hepatoma, colorectal cancer, lung cancer, breast cancer, and oral cancer, respectively. The incidence of PM in NPC was 91.34. Taken together, the above findings suggested that NPC was the most common malignancy in patients with DM. These numbers indicated that there was an almost 5–15 times higher incidence in NPC than other malignancies in myositis, which demonstrated a strong association between DM and NPC.

Possible associations between NPC and DM. NPC has been suggested to be an EBV-associated malignancy. One study collected 172 NPC patients with and without DM and explored the EBV status. They used the two most widely tested EBV-related antibodies, IgA against early antigen antibody (EA-IgA) and IgA against viral capsid antigen (VCA-IgA), which have been used to assist with the diagnosis and prediction of the prognosis of NPC. They found that the NPC group with DM had higher EBV VCA-IgA titers than the group without DM (p = 0.017). Another study showed significantly higher EBV genome positivity in patients with PM/DM with NPC than in those without malignancy (odds ratio = 43.9, p < 0.01), which indicated positive associations of EBV with PM/DM and NPC. In addition, EBV has been associated with many autoimmune diseases. Although the etiology of DM is still unknown, these findings might suggest an association between EBV infection and DM.

Recent advances in the understanding of the programmed death-1 (PD-1) checkpoint pathway in cancer and autoimmunity might help us understand the role of EBV in NPC and myositis. The PD-1 pathway is considered a physiologic immune regulatory pathway that enables tolerance to self-antigens via the downregulation of the immune response. In previous studies, approximately 70% of EBV-positive NPC patients expressed programmed death-ligand 1 (PD-L1), and patients with DM with malignancy had higher levels of soluble PD-L1 in serum than nonmalignancy patients, which might provide evidence that EBV facilitates NPC cell production of PD-L1 and decreases local and systemic immune reactions. In addition, persistent exposure to antigens in myositis may lead to T cell exhaustion and senescence, which might be related to the PD-1/PD-L1 pathway. Less effective T cells have been shown to invade skeletal muscle tissue and contribute to a lower degree of inflammation in myofibers. From the above evidence, we hypothesized that patients with NPC, DM, and EBV infection might have less muscle inflammation than those without malignancy because of the activation of the PD-L1 pathway and T cell dysfunction. This hypothesis would be supported by lower serum levels of CPK, which is one of the muscle enzymes, in patients with NPC, DM, and EBV infection than in those without malignancy. In our study, patients with DM associated with malignancy had significantly lower serum levels of CPK than those without malignancy (p < 0.05). Although previous studies showed that both increased and decreased levels of CPK could be risk factors for malignancy in myositis, our findings suggested that lower serum levels of CPK were associated with myositis with malignancy, and this finding might be attributed to effects on the PD-L1 pathway and T cell senescence. Regarding the survival of patients with myositis and malignancy, some studies showed decreased survival of patients with DM with malignancy compared with those without malignancy. Although we do not know the survival difference between patients with DM and without NPC, patients with NPC with DM did not have significantly different survival from those without DM.

Risk factors for malignancy in myositis. We identified several risk factors associated with malignancy in myositis. Regarding demographic factors, old age played a significant role in malignancy associated with DM, while male contributed to malignancy associated with PM. In previous studies, some researchers found an increased incidence of malignancy in males, while others did not find similar results. In our study, patients with PM had colorectal, lung and prostate cancers, which are more common in male than female patients in our
national cancer registry data. In terms of comorbidities, we did not find significant associations among diabetes mellitus, hypertension and interstitial lung disease and myositis-associated malignancy in our study, which is in agreement with a previous study\textsuperscript{51}. Another study showed that a past history of diabetes mellitus was associated with an increased risk of malignancy in patients with myositis, which may be related to insulin-like growth factors, oxidative stress and DNA damage\textsuperscript{52}. Our study showed serum tumor markers (CEA and AFP) and autoimmune markers (ANA) were associated with malignancies in patients with myositis. However, Lim et al. found no significant associations of increased tumor markers with the occurrence of malignancies, and they suggested that tumor markers were not useful for malignancy screening for patients with myositis\textsuperscript{52}. Although our results showed significant differences between myositis patients with malignancy and without malignancy, the numbers of malignancy cases were not large enough, and interpretations should be made very cautiously.

Limitations. Several limitations should be addressed in the current study. First, our study was from a single center and analyzed a retrospective cohort of patients with DM and PM and malignancy with a long observational period (19 years) and thus does not represent all patients with myositis and malignancy. Although we used two nationwide cohort studies as our references and some differences were found, such as differences in malignancy incidence and risk factors, some consistent findings were found, such as NPC being the most common malignancy in DM and approximately 50% of malignancies being diagnosed within 1 year after the diagnosis of DM. Second, EMR information cannot provide detailed clinical symptoms/signs, such as dysphasia, muscle power or even cutaneous lesions, which have been reported as risk factors for malignancy\textsuperscript{53}. The differences in the severity of disease symptoms (confounding factors), the serum CPK levels at different stages of the disease (measurement errors) and the loss of some patients to follow-up (selection bias) may also limit the generalization of our findings. Third, we did not study serum myositis-specific autoantibodies, which have been reported to be related to malignancy in myositis\textsuperscript{53,54}. Future studies including the above data may improve the sensitivity of malignancy diagnosis. Other issues include using different strategies to screen organ-specific malignancies, such as tumor markers and conventional and modern imaging techniques, which may increase the malignancy detection rate and shorten the time between myositis diagnosis and the detection of malignancy. Recent studies suggest that tumor markers are not very useful for malignancy screening; thus, we need to develop updated guidelines to improve malignancy detection in myositis\textsuperscript{55,56}.

Conclusion

Our study showed evidence of increased malignancy incidences in patients with DM and PM. Most malignancies in patients with DM occur within 1 year after myositis diagnosis. Specific risk factors for malignancy in myositis include old age (age ≥ 45 years old), sex (male) and low serum CPK levels. Low serum levels of CPK in myositis associated with malignancy could be explained by the activation of the PD-L1 pathway and T cell senescence.

Data availability

Additional clinical data are available from laboratory studies. Please contact PWL: paiwei24@gmail.com if this information is of interest.

Received: 21 June 2020; Accepted: 14 January 2021
Published online: 25 February 2021

References

1. Mammen, A. L. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann. N. Y. Acad. Sci. 1184, 134–153. https://doi.org/10.1111/j.1749-6632.2009.05119.x (2010).
2. Findlay, A. R., Goyal, N. A. & Mozaffar, T. An overview of polymyositis and dermatomyositis. Muscle Nerve 51, 638–656. https://doi.org/10.1002/mus.24566 (2015).
3. Smoyer-Tomic, K. E., Amato, A. A. & Fernandez, A. W. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet. Disord. 13, 103. https://doi.org/10.1186/1471-2474-13-103 (2012).
4. Furst, D. E., Amato, A. A., Jonga, S. R., Gajria, K. & Fernandez, A. W. Epidemiology of adult idiopathic inflammatory myopathies in a US managed care plan. Muscle Nerve 45, 676–683. https://doi.org/10.1002/mus.23302 (2012).
5. Kuo, C. F. et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br. J. Dermatol. 165, 1273–1279. https://doi.org/10.1111/j.1365-2133.2011.10595.x (2011).
6. G. S. Polymyositis. Berl Klin Wochenschr; 20:489 (1916).
7. Barnes, B. E. & Mawr, B. Dermatomyositis and malignancy. A review of the literature. Ann. Intern Med. 84, 68–76. https://doi.org/10.7326/0003-4819-84-1-68 (1976).
8. Sigurgeirsson, B., Lindelof, B., Edhag, O. & Allander, E. Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N. Engl. J. Med. 326, 363–367. https://doi.org/10.1056/NEJM199206233262602 (1992).
9. Buchbinder, R., Forbes, A., Hall, S., Dennett, X. & Giles, G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: A population-based cohort study. Ann. Intern. Med. 134, 1087–1095. https://doi.org/10.7326/0003-4819-134-12-200106190-00008 (2001).
10. Chen, Y. J. et al. Cancer risks of dermatomyositis and polymyositis: A nationwide cohort study in Taiwan. Arthritis Res. Ther. 12, R70. https://doi.org/10.1186/ar2987 (2010).
11. Qiang, J. K., Kim, W. B., Baibergenova, A. & Alhusayen, R. Risk of malignancy in dermatomyositis and polymyositis. J. Cutan. Med. Surg. 21, 131–136. https://doi.org/10.1089/jcms.2013.0475 (2017).
12. Limaye, V. et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol. Int. 33, 965–971. https://doi.org/10.1007/s00296-012-2489-y (2013).
13. Aitio, A., Pukkala, E. & Isomaki, H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J. Rheumatol. 22, 1300–1303 (1995).
14. So, M. W., Koo, B. S., Kim, Y. G., Lee, C. K. & Yoo, B. Idiopathic inflammatory myopathy associated with malignancy: A retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J. Rheumatol. 38, 2432–2435. https://doi.org/10.3899/ jreum.110320 (2011).

15. Tsinakou, E. & Mammen, A. L. Idiopathic inflammatory myopathies and malignancy: A comprehensive review. Clin. Rev. Allergy Immunol. 52, 20–33. https://doi.org/10.1007/s12016-015-8511-x (2017).

16. Yang, Z., Lin, E., Qin, B., Liang, Y. & Zhong, R. Polymyositis/dermatomyositis and malignancy risk: A meta-analysis study. J. Rheumatol. 42, 282–291. https://doi.org/10.3899/jrheum.140566 (2015).

17. Ungprasert, P. et al. Clinical features of inflammatory myopathies and their association with malignancy: A systematic review in Asian population. ISRN Rheumatol. 2013, 509354. https://doi.org/10.1155/2013/509354 (2013).

18. Hsu, Y. Y. et al. Health disparities of employees in Taiwan with major cancer diagnosis from 2004 to 2015: A nation- and population-based analysis. Int. J. Environ. Res. Public Health 16, 2019. https://doi.org/10.3390/ijerph16111982 (2019).

19. Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403–407. https://doi.org/10.1056/NEJM197502220920807 (1975).

20. Fang, Y. F., Wu, Y. J., Kuo, C. F., Luo, S. F. & Yu, K. H. Malignancy in dermatomyositis and polymyositis: Analysis of 192 patients. Clin. Rheumatol. 35, 1977–1984. https://doi.org/10.1007/s10067-016-3296-8 (2016).

21. Clark, K. E. N. & Isenberg, D. A. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur. J. Neurol. 25, 13–23. https://doi.org/10.1111/ene.13357 (2018).

22. Hill, C. L. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 357, 96–100. https://doi.org/10.1016/S0140-6736(00)3540-6 (2001).

23. Chen, D. et al. Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China. Clin. Exp. Rheumatol. 32, 615–621 (2014).

24. Teoh, J. W., Yunus, R. M., Hassan, F., Ghazali, N. & Abidin, Z. A. Nasopharyngeal carcinoma in dermatomyositis patients: A 10-year retrospective review in Hospital Selayang, Malaysia. Rep. Pract. Oncol. Radiother. 19, 332–336. https://doi.org/10.1016/j.rpor.2014.02.005 (2014).

25. Ang, P., Sugeng, M. W. & Chua, S. H. Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: A 5-year retrospective review of their clinical characteristics and association with malignancy. Ann. Acad. Med. Singap. 29, 219–223 (2000).

26. Liu, Y. et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma. Ann. N.Y. Acad. Sci. 1128, 1461–1469 (1991).

27. Pathmanathan, R. et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein–Barr virus-infected neoplasia. Am. J. Pathol. 146, 1335–1367 (1995).

28. Chen, Y. et al. Diagnostic value of serum Epstein–Barr virus capsid antigen-IgA for nasopharyngeal carcinoma. N. Engl. J. Med. 350, 2461–2470. https://doi.org/10.1056/NEJMoa032260 (2004).

29. Huang, P. Y. et al. Paired study of 172 cases of nasopharyngeal carcinoma with or without dermatomyositis. Acta Otolaryngol. 134, 824–830. https://doi.org/10.3109/00016499.2014.913312 (2014).

30. Yu, M. C. Diet and nasopharyngeal carcinoma. FEMS Microbiol. Immunol. 2, 235–242. https://doi.org/10.1111/j.1574-6968.1999.tb03524.x (1999).

31. Wang, C. et al. Diet Quality scores and risk of nasopharyngeal carcinoma in Chinese adults: A case–control study. Nutrients 8, 112. https://doi.org/10.3390/nu8030112 (2016).

32. Wu, T. C. et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein–Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am. J. Pathol. 138, 1461–1469 (1991).

33. Chen, D. Y. et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein–Barr virus connection?. J. Clin. Virol. 49, 290–295. https://doi.org/10.1016/j.jcv.2010.08.015 (2010).

34. Barzilai, O. et al. Epstein–Barr virus and cytomegalovirus in autoimmune diseases: Are they truly notorious? A preliminary report. Ann. N. Y. Acad. Sci. 1108, 567–577. https://doi.org/10.1196/annals.1422.059 (2007).

35. Selva-O’Callaghan, A., Mammen, A. L. Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. Neuromuscul. Disord. 29, 819–825. https://doi.org/10.1016/j.nmd.2019.09.014 (2019).

36. Pedersen, A., Azoulay-Allaguet, J., Strazza, M., Silverman, G. J. & Mog, A. Programmed death 1 pathway in cancer and autoimmunity. Clin. Immunol. 153, 145–152. https://doi.org/10.1016/j.clinim.2014.04.010 (2014).

37. Chen, H. et al. Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis. J. Rheumatol. 45, 835–840. https://doi.org/10.3899/jrheum.170544 (2018).

38. Larbacharensb, N. et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein–Barr virus-associated nasopharyngeal carcinoma. J. Clin. Oncol. 41, 1204–1210. https://doi.org/10.1097/COJ.0000000000004499 (2018).

39. Knauss, S. et al. PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited. Neurol. Neuroimmunol. Neuroinflamm. 6, e558. https://doi.org/10.12112/NXLI0000000000000558 (2019).

40. Chen, Y. J., Wu, C. Y. & Shen, J. L. Predicting factors of malignancy in dermatomyositis and polymyositis: A case–control study. Br. J. Dermatol. 164, 832–831. https://doi.org/10.1111/bjd.15334 (2011).

41. Lee, S. W., Jung, S. Y., Park, M. C., Park, Y. B. & Lee, S. K. Malignancies in Korean patients with inflammatory myopathy. J. Yonsei Med. J. 47, 519–523. https://doi.org/10.3349/jymj.2006.47.5.519 (2006).

42. Motomura, K., Yamashita, H., Yamada, S., Takahashi, Y. & Kaneko, H. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: A 25-year retrospective study. Rheumatol. Int. 39, 1733–1739. https://doi.org/10.1007/s00296-019-04426-z (2019).

43. Andras, C. et al. Dermatomyositis and polymyositis associated with malignancy: A 21-year retrospective study. J. Rheumatol. 35, 438–444 (2008).
50. Wakata, N., Kurihara, T., Saito, E. & Kinoshita, M. Polymyositis and dermatomyositis associated with malignancy: A 30-year retrospective study. *Int. J. Dermatol.* **41**, 729–734. [https://doi.org/10.1046/j.1365-4632.2002.01648.x](https://doi.org/10.1046/j.1365-4632.2002.01648.x) (2002).

51. Yu, K. H. *et al.* Survival analysis of patients with dermatomyositis and polymyositis: Analysis of 192 Chinese cases. *Clin. Rheumatol.* **30**, 1595–1601. [https://doi.org/10.1007/s10067-011-1840-0](https://doi.org/10.1007/s10067-011-1840-0) (2011).

52. Lim, C. H. *et al.* The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. *SAGE Open Med.* **6**, 2050312118781895. [https://doi.org/10.1177/2050312118781895](https://doi.org/10.1177/2050312118781895) (2018).

53. Nakashima, R. Clinical significance of myositis-specific autoantibodies. *Immunol. Med.* **41**, 103–112. [https://doi.org/10.1080/25785826.2018.1531188](https://doi.org/10.1080/25785826.2018.1531188) (2018).

54. Li, S. *et al.* The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. *Clin. Rheumatol.* **38**, 2171–2179. [https://doi.org/10.1007/s10067-019-04503-7](https://doi.org/10.1007/s10067-019-04503-7) (2019).

55. Selva-O’Callaghan, A., Martinez-Gomez, X., Trallero-Araguas, E. & Pinal-Fernandez, I. The diagnostic work-up of cancer-associated myositis. *Curr. Opin. Rheumatol.* **30**, 630–636. [https://doi.org/10.1097/BOR.0000000000000535](https://doi.org/10.1097/BOR.0000000000000535) (2018).

**Acknowledgements**

The authors thank the statistical assistance and wish to acknowledge the support of the Maintenance Project of the Center for Big Data Analytics and Statistics (Grant CLRPG3D0046) at Chang Gung Memorial Hospital for study design and monitor, data analysis and interpretation.

**Author contributions**

J.L.H.: design and conceptualization study, analyzed the data, drafted the manuscript for intellectual content. M.-F.L.: major role in the acquisition of data. C.-C.C.: major role in the acquisition of data. H.-C.K.: major role in the acquisition of data. R.-K.L.: major role in the acquisition of data. H.-S.C.: major role in the acquisition of data. C.-M.C.: major role in the acquisition of data. Y.-R.W.: major role in the acquisition of data. K.-H.C.: major role in the acquisition of data. C.-W.C.: major role in the acquisition of data. PW.L.: analyzed the data. C.-C.H.: major role in the acquisition of data. L.-S.R.: interpreted the data; revised the manuscript for intellectual content.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to L.-S.R.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2021